The Tumor Immune Microenvironment in Breast Cancer Progression

Overview

Journal Acta Oncol

Specialty Oncology

Date 2024 May 23

PMID 38779867

Authors

Marit Otterlei Fjortoft

Kanutte Huse

Inga Hansine Rye

Affiliations

Soon will be listed here.

Abstract

Background: The tumor microenvironment significantly influences breast cancer development, progression, and metastasis. Various immune cell populations, including T cells, B cells, NK cells, and myeloid cells exhibit diverse functions in different breast cancer subtypes, contributing to both anti-tumor and pro-tumor activities.

Purpose: This review provides an overview of the predominant immune cell populations in breast cancer subtypes, elucidating their suppressive and prognostic effects. We aim to outline the role of the immune microenvironment from normal breast tissue to invasive cancer and distant metastasis.

Methods: A comprehensive literature review was conducted to analyze the involvement of immune cells throughout breast cancer progression.

Results: In breast cancer, tumors exhibit increased immune cell infiltration compared to normal tissue. Variations exist across subtypes, with higher levels observed in triple-negative and HER2+ tumors are linked to better survival. In contrast, ER+ tumors display lower immune infiltration, associated with poorer outcomes. Furthermore, metastatic sites commonly exhibit a more immunosuppressive microenvironment.

Conclusion: Understanding the complex interaction between tumor and immune cells during breast cancer progression is essential for future research and the development of immune-based strategies. This comprehensive understanding may pave the way for more effective treatment approaches and improved patients outcomes.

Citing Articles

Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq.

Shi Y, Yu Y, Zhao J, Huang L, Wang Q, Sun Q Discov Oncol. 2025; 16(1):114.

PMID: 39899181 PMC: 11790537. DOI: 10.1007/s12672-025-01812-z.

Self-Tumor Antigens in Solid Tumors Turned into Vaccines by α-gal Micelle Immunotherapy.

Galili U Pharmaceutics. 2024; 16(10).

PMID: 39458595 PMC: 11510312. DOI: 10.3390/pharmaceutics16101263.

Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare.

Bjorgo E, Fagereng G, Russnes H, Smeland S, Tasken K, Helland A Acta Oncol. 2024; 63:487-490.

PMID: 38910311 PMC: 11332496. DOI: 10.2340/1651-226X.2024.24954.

References

Blomberg O, Kos K, Spagnuolo L, Isaeva O, Garner H, Wellenstein M . Neoadjuvant immune checkpoint blockade triggers persistent and systemic T activation which blunts therapeutic efficacy against metastatic spread of breast tumors. Oncoimmunology. 2023; 12(1):2201147. PMC: 10114978. DOI: 10.1080/2162402X.2023.2201147. View

Campbell K, Hasegawa J . Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013; 132(3):536-544. PMC: 3775709. DOI: 10.1016/j.jaci.2013.07.006. View

Saleh R, Elkord E . FoxP3 T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020; 490:174-185. DOI: 10.1016/j.canlet.2020.07.022. View

Mahmoud S, Lee A, Paish E, Macmillan R, Ellis I, Green A . Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2011; 65(2):159-63. DOI: 10.1136/jclinpath-2011-200355. View

Mansfield A, Heikkila P, von Smitten K, Vakkila J, Leidenius M . The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch. 2012; 461(6):639-46. DOI: 10.1007/s00428-012-1338-4. View

Liao N, Li C, Cao L, Chen Y, Ren C, Chen X . Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. Breast Cancer. 2022; 30(1):77-87. DOI: 10.1007/s12282-022-01400-x. View

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L . The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol. 2021; 11:610303. PMC: 7991834. DOI: 10.3389/fonc.2021.610303. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Goff S, Danforth D . The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. Clin Breast Cancer. 2020; 21(1):e63-e73. PMC: 7775885. DOI: 10.1016/j.clbc.2020.06.011. View

10.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

11.

Bouzidi L, Triki H, Charfi S, Ben Kridis W, Derbel M, Ayadi L . Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues. Clin Breast Cancer. 2021; 21(6):e738-e747. DOI: 10.1016/j.clbc.2021.02.003. View

12.

Albrecht A, Hartmann B, SCHOLTEN C, Huber J, Kalinowska W, Zielinski C . Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women. Maturitas. 1996; 25(3):217-22. DOI: 10.1016/s0378-5122(96)01063-8. View

13.

Kumar S, Wilkes D, Samuel N, Blanco M, Nayak A, Alicea-Torres K . ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J Clin Invest. 2018; 128(11):5095-5109. PMC: 6205409. DOI: 10.1172/JCI99673. View

14.

Buisseret L, Garaud S, De Wind A, Van den Eynden G, Boisson A, Solinas C . Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017; 6(1):e1257452. PMC: 5283629. DOI: 10.1080/2162402X.2016.1257452. View

15.

van Pul K, Vuylsteke R, van de Ven R, Te Velde E, Rutgers E, van den Tol P . Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. J Immunother Cancer. 2019; 7(1):133. PMC: 6530094. DOI: 10.1186/s40425-019-0605-1. View

16.

Moshina N, Sebuodegard S, Lee C, Akslen L, Tsuruda K, Elmore J . Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts. Radiology. 2018; 288(2):343-352. DOI: 10.1148/radiol.2018172972. View

17.

Kumar T, Nee K, Wei R, He S, Nguyen Q, Bai S . A spatially resolved single-cell genomic atlas of the adult human breast. Nature. 2023; 620(7972):181-191. PMC: 11443819. DOI: 10.1038/s41586-023-06252-9. View

18.

Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T . FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2014; 1(4):625-632. PMC: 3915667. DOI: 10.3892/mco.2013.107. View

19.

Tivari S, Lu H, Dasgupta T, De Lorenzo M, Wieder R . Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence. Cell Commun Signal. 2018; 16(1):48. PMC: 6098600. DOI: 10.1186/s12964-018-0259-5. View

20.

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View